Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7854392 | 0.86 | TSHR (0.70) | KMT2ATSHRRXFP1KEAP1MEN1 | |
| SCHEMBL2568299 | 0.85 | RECQL (0.58) | KMT2ATSHRRXFP1KEAP1MEN1 | |
| SCHEMBL3072539 | 0.83 | LMNA (0.70) | CA1CA2CA9TSHRKEAP1 | |
| SCHEMBL5480533 | 0.82 | POLB (0.62) | CA2KMT2ATSHRMEN1HTR6 | |
| SCHEMBL5737105 | 0.82 | TSHR (0.58) | CA1CA2CA9TSHRRXFP1 | |
| SCHEMBL13072612 | 0.79 | CA1 (0.64) | CA1CA2CA9KMT2ATSHR | |
| SCHEMBL2240809 | 0.79 | ALDH1A1 (0.71) | CA1CA2CA9KMT2ATSHR | |
| SCHEMBL1970942 | 0.79 | KMT2A (0.71) | CA1CA2CA9KMT2ATSHR | |
| SCHEMBL6832818 | 0.79 | KMT2A (0.71) | CA1CA2CA9KMT2AKEAP1 | |
| SCHEMBL21893366 | 0.79 | CA2 (0.62) | CA1CA2CA9KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634948-B1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | INST NAT SANTE RECH MED (FR) | 2025-09-17 | — | — | EP | disclosed |
| EP-3634949-B1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INST NAT SANTE RECH MED (FR) | 2025-03-19 | — | — | EP | disclosed |
| US-11795144-B2 | Inhibitors of RAC1 and uses thereof for treating cancers | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-10-24 | — | — | US | disclosed |
| US-11795144-B2 | Inhibitors of RAC1 and uses thereof for treating cancers | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-10-24 | — | — | US | disclosed |
| US-11607419-B2 | Inhibitors of RAC1 and uses thereof for inducing bronchodilatation | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-03-21 | — | — | US | disclosed |
| WO-2018224563-A9 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-04-22 | — | — | WO | disclosed |
| WO-2018224563-A9 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-04-22 | — | — | WO | disclosed |
| US-20210077508-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | NANTES UNIVERSITE (FR) | 2021-03-18 | — | — | US | disclosed |
| US-20210077508-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | NANTES UNIVERSITE (FR) | 2021-03-18 | — | — | US | disclosed |
| EP-3634948-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2020-04-15 | — | — | EP | disclosed |
| EP-3634949-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2020-04-15 | — | — | EP | disclosed |
| US-20200095199-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | NANTES UNIVERSITE (FR) | 2020-03-26 | — | — | US | disclosed |
| US-20200095199-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | NANTES UNIVERSITE (FR) | 2020-03-26 | — | — | US | disclosed |
| WO-2018224563-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018224560-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-12-13 | — | — | WO | disclosed |
| EP-3412652-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-12-12 | — | — | EP | disclosed |
| EP-3412651-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-12-12 | — | — | EP | disclosed |
| US-6638921-B1 | Pharmaceutically acceptable derivatives thereof Cx, R1 and R2 being as defined in the disclosure may be used to inhibit the activity of HIV integrase. | PHARMACOR INC. (CA) | 2003-10-28 | — | — | US | disclosed |
| WO-2003082881-A2 | PYRIDOXAL-5-PHOSPHATE DERIVATIVES AS HIV INTEGRASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795144-B2 | Inhibitors of RAC1 and uses thereof for treating cancers | RAC1, KRAS, CYRIB | CA1 2055/4885CA2 557/4885CA9 1079/4885 |
| US-11607419-B2 | Inhibitors of RAC1 and uses thereof for inducing bronchodilatation | RAC1, CYRIB, ARHGDIB | CA1 3035/4885CA2 343/4885CA9 2561/4885 |
| US-20210077508-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION | RAC1, CYRIB, ARHGDIB | CA1 3035/4885CA2 343/4885CA9 2561/4885 |
| US-20200095199-A1 | INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS | RAC1, KRAS, CYRIB | CA1 2055/4885CA2 557/4885CA9 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.